  |
Publication AbstractsEffects of almitrine bismesylate in a microswine model of hypoxemic hypothermiaGentile BJ, Durkot MJ, Krestel BA, Sils IV, Tartarini KA, English DA, Alkhyyat AMAviat Space Environ Med 1997; 68:824-8 AbstractWe have developed an anesthetized microswine model of hypoxemic hypothermia and re-warming for testing prophylaxes and treatments. The respiratory stimulant almitrine bismesylate (ALM) was considered as a potential field expedient therapy for hypoxemic hypothermia. Preliminary experiments demonstrated that five consecutive 100 µg · kg-1 ALM intravenous (iv) doses given to normothermic microswine 3-4 min apart increased minute ventilation from an average of 3.4 L · min-1 to 4.5 L · min-1 (n = 2). However, when either a single iv ALM dose of 150 µg · kg-1 (n = 1) or three consecutive 100 µg · kg-1 iv doses were given 15 min apart (n = 1) to hypoxemic hypothermic microswine with a mean esophageal temperature (Tes) = 28.8°C, and a mean arterial O2 partial pressure (PaO2) = 49 mmHg, the hypoxemia was potentiated (mean PaO2 = 32 mmHg) and respiratory arrest ensued. Other experiments using continuous ALM iv infusion (1.0 µg · kg-1 · min-1) in hypoxemic hypothermic microswine (n = 6, Tes = 30.6 ± 0.5, PaO2 = 55.4 ± 12.9) did not demonstrate significant (p < 0.05) cardiorespiratory differences (ventilation, heart rate, blood pressure, blood gases) when compared to hypoxemic hypothermic controls (n = 6, Tes = 30.7 ± 0.5, PaO2 = 53. ± 13.6). These results suggest that high dose iv bolus administration of ALM is not indicated as a potential field expedient therapy for hypoxemic hypothermia, while further work is required to assess the potential efficacy of other continuous low dose iv infusion regimens.
Information on subscribing, and on obtaining copies of an article or of an entire issue. Table of Contents for Volume 68, Number 9 of the ASEM journal.
|
 |
 |